



(51) International Patent Classification:

C07D 413/10 (2006.01) **A61P 25/00** (2006.01)
A61K 31/422 (2006.01) **C07D 209/46** (2006.01)

(21) International Application Number:

PCT/SE2009/050682

(22) International Filing Date:

8 June 2009 (08.06.2009)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/059,485 6 June 2008 (06.06.2008) US

(71) Applicant (for all designated States except US): **ASTRAZENECA AB** [SE/SE]; S-151 85 Södertälje (SE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **CACCIOLA, Joseph** [US/US]; AstraZeneca R&D Wilmington, Wilmington, Delaware 19850-5437 (US). **EMPFIELD, James** [US/US]; AstraZeneca R&D Wilmington, Wilmington, Delaware 19850-5437 (US). **FOLMER, James** [US/US]; AstraZeneca R&D Wilmington, Wilmington, Delaware 19850-5437 (US). **HUNTER, Angela M** [US/US]; AstraZeneca R&D Wilmington, Wilmington, Delaware 19850-5437 (US). **THRÖNER, Scott** [US/US]; AstraZeneca R&D Wilmington, Wilmington, Delaware 19850-5437 (US).

(74) Agent: **ASTRAZENECA AB**; AstraZeneca Intellectual Property, S-151 85 Södertälje (SE).


(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: ISOXAZOLE DERIVATIVES AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS



(57) Abstract: Compounds in accord with Formula (I); wherein R¹, R², R³ and R⁴ are as defined in the specification, pharmaceutically acceptable salts, methods of making, pharmaceutical compositions containing and methods for using the same.